Lecanemab and donanemab (Kisunla), another anti-amyloid treatment, won approval based on evidence that they slowed cognitive ...

While the drugs certainly contribute to weight loss and health gains, they also cause a decline in muscle that some doctors ...

In a recent study, researchers found adverse events were rare and manageable among clinic patients with very mild or mild Alzheimer's disease who received lecanemab infusions.

A new study has found that a common class of medications could dramatically decrease the risk of developing the neurodegenerative disorder.

Valinor Discovery, a company pioneering machine learning-powered simulation of therapeutic performance to derisk drug ...

The ALS therapy ATLX-1282 was developed with AIchemab's platform, which uses AI to identify therapeutic targets for difficult ...

Researchers found the PHGDH gene directly causes Alzheimer’s and discovered a drug-like molecule, NCT-503, that may help ...

The Food and Drug Administration's approval in 2023 of lecanemab - a novel Alzheimer's therapy shown in clinical trials to modestly slow disease progression - was met with enthusiasm by many in the ...

Scientists are calling for clinical trials after discovering a drug already prescribed for a virus affecting millions may also help prevent Alzheimer's too.